Russia authorizes Pfizer to conduct clinical trials for its experimental COVID-19 drug named Paxlovid, which will continue until March 2023. (The Hill) COVID-19 pandemic in Russia, COVID-19 drug developmentCOVID-19 pandemic in EuropeCOVID-19 pandemic link embed save